Introduction {#sec1}
============

Polycystic ovarian syndrome (PCOS) is a highly prevalent disorder affecting multiple aspects of a women's overall health, with long-term effects that transcend well beyond the reproductive age \[[@B1]\]. Clinically, PCOS is characterized by hyperandrogenism manifested by hirsutism, acne and androgenic alopecia \[[@B4]\]. Patients with PCOS demonstrate reproductive abnormalities \[[@B5]\], marked insulin resistance \[[@B6]\], increased risk for Type 2 diabetes mellitus \[[@B7]\], coronary heart disease \[[@B8]\], atherogenic dyslipidemia \[[@B9]\], cerebrovascular morbidity \[[@B10]\], and anxiety and depression \[[@B11]\]. Although it was first reported in 1935 by Stein et al., the etiology remains unclear. Data from many studies suggest that genetics is very important in the development of PCOS \[[@B12]\].

Vascular endothelial growth factor (VEGF) gene, also known as VEGFA, VPF and MVCD1, locates at 6p21.1 and contains nine exon counts, and is a member of the PDGF/VEGF growth factor family \[[@B13]\]. It encodes a heparin-binding protein, which exists as a disulfide-linked homodimer. This growth factor induces proliferation and migration of vascular endothelial cells and is essential for both physiological and pathological angiogenesis \[[@B14]\].

VEGF plays a critical role in ovarian folliculogenesis and normal reproductive function \[[@B14]\], highlighted by the findings that women with PCOS had increased serum levels of VEGF, which paralleled increases in Doppler flow velocities within ovarian vessels \[[@B15],[@B16]\]. High vascularization may result in abnormal growth of the theca interna, the site of androgen steroidogenesis, leading to hyperandrogenism, a hallmark of PCOS \[[@B17]\]. Several single-nucleotide polymorphisms (SNPs) were identified within the VEGF gene, of which some were functional, directly affecting VEGF secretion and its serum expression \[[@B18]\].

So far, many studies have investigated the association between *VEGF* polymorphisms and PCOS risk. However, the results were not conclusive or consistent. Considering the vital role of *VEGF* gene in the development of PCOS, we conducted a timely meta-analysis including 11 SNPs \[[@B21]\] to derive a more comprehensive estimation of the association between *VEGF* gene polymorphisms and PCOS susceptibility to identify some significant biomarkers.

Materials and methods {#sec2}
=====================

Identification and eligibility of relevant studies {#sec2-1}
--------------------------------------------------

We applied the PubMed, Embase, WanFang and CNKI databases using the key words 'VEGF or VEGFA or VPF', 'PCOS or Polycystic ovarian syndrome' and 'polymorphism' or 'variant' to identify including studies. The last search was updated on May 10, 2019. Finally, 29 case--control studies about 11 different SNPs were retrieved.

Inclusion criteria and exclusion criteria {#sec2-2}
-----------------------------------------

Including studies had to meet following criteria: (1) address the correlation between PCOS risk and the *VEGF* gene SNPs; (2) be a case--control study, and (3) have sufficient genotype (wild-type and mutant type) numbers in each case and control group. The following exclusion criteria were used: (1) lack of a control population; (2) lack of available genotype frequency data; and (3) duplicated studies.

Data extraction {#sec2-3}
---------------

The following items were selected: the first author's last name, the year of publication, the country of origin, the ethnicity of subjects, SNP type, total number of case and control groups, source of control (SOC), the number of each genotype frequency in the case/control groups, the Hardy--Weinberg equilibrium (HWE) in the control group, and the genotyping method. Ethnicity was categorized as Asian, European, Mixed and African.

Statistical analysis {#sec2-4}
--------------------

Odds ratio (OR) with 95% confidence intervals (CI) were used to measure the strength of the association between the *VEGF* gene SNPs and PCOS risk. The statistical significance of the summary OR was determined with the *Z*-test. A heterogeneity assumption was evaluated among studies using a chi-square-based *Q*-test. If a *P-*value of \< 0.10 for the *Q*-test indicated heterogeneity among the studies. If significant heterogeneity was detected, the random-effects model (DerSimonian-Laird method) was used. Otherwise, the fixed-effects model (Mantel--Haenszel method) was applied \[[@B30],[@B31]\].

We investigated the relationship between genetic variants of the *VEGF* gene SNPs and PCOS risk by the allelic contrast (1 vs. 2), homozygote comparison (1/1 vs. 2/2), dominant genetic model (1/1+1/2 vs. 2/2), heterozygote comparison (1/2 vs. 2/2) and recessive genetic model (1/1 vs. 1/2+2/2). A sensitivity analysis was performed by omitting studies, one after another, to assess the stability of results. The departure of the *VEGF* gene SNPs from expected frequencies under HWE was assessed in controls using the Pearson chi-square test (*P* \< 0.05 was considered significant). Funnel plot asymmetry was assessed using Begg's test and publication bias was assessed using Egger's test \[[@B32]\], both the *P*-value \< 0.05 is considered as significant. All statistical tests for this meta-analysis were performed with Stata software (version 11.0; StataCorp LP, College Station, TX).

Network of gene interaction of *VEGF* gene {#sec2-5}
------------------------------------------

To more complete understanding of the role of VEGF in PCOS, the network of gene--gene interactions for VEGF gene was utilized through String online server (<http://string-db.org/>) \[[@B33]\].

Results {#sec3}
=======

Study characteristics {#sec3-1}
---------------------

In total, 73 articles were collected from the PubMed, Embase, CNKI and WanFang databases via a literature search using different combinations of above keywords. As shown in [Figure 1](#F1){ref-type="fig"}, 64 articles were excluded (such as duplications, irrelevant articles, reviews and other gene's polymorphisms). Finally, 9 different articles including 11 SNPs were included in our current meta-analysis ([Figure 1](#F1){ref-type="fig"}). Study characteristics from the published studies on the relationship between the *VEGF* gene SNPs and PCOS risk are summarized in [Table 1](#T1){ref-type="table"}. In all the studies, the controls were women under normal pregnancy. The detail of 11 SNPs were rs2010963 or -634 (three case--control studies including 632 cases and 622 controls), +9812 (two case--control studies including 212 cases and 183 controls), +13553 (two case--control studies including 208 cases and 184 controls), -460 (two case--control studies including 263 cases and 285 controls), +405 (two case--control studies including 263 cases and 285 controls), rs699947 or -2578 (four case--control studies including 724 cases and 782 controls), rs833061 (three case--control studies including 618 cases and 673 controls), rs1570360 or -1154 (four case--control studies including 697 cases and 737 controls), rs833068 (two case--control studies including 500 cases and 540 controls), rs3025020 (two case--control studies including 500 cases and 540 controls), and rs3025039 or +936 (three case--control studies including 586 cases and 628 controls).

![Flowchart illustrating the search strategy used to identify association studies for *VEGF* gene polymorphisms and PCOS risk](bsr-40-bsr20191691-g1){#F1}

###### Basic information for included studies of the association between polymorphisms in *VEGF* gene and PCOS susceptibility

  Author      Year   Country   Ethnicity   SNPs                Case   Control   SOC   Cases   Controls   HWE                              
  ----------- ------ --------- ----------- ------------------- ------ --------- ----- ------- ---------- ----- ---- ----- ----- --------- ------------
  Lee         2008   Korea     Asian       rs2010963 (-634)    132    99        HB    26      60         46    20   45    34    0.47      TaqMan
  Almawi      2016   Bahrain   Asian       rs2010963 (-634)    382    393       PB    57      142        183   42   190   161   0.01      TaqMan
  Huang       2018   China     Asian       rs2010963 (-634)    118    130       HB    13      45         60    19   64    47    0.71      PCR-LDR
  Lee         2008   Korea     Asian       +9812               132    99        HB    6       36         90    12   29    58    0.01      TaqMan
  Ding        2009   China     Asian       +9812               80     84        HB    6       24         50    16   24    44    0.001     sequencing
  Lee         2008   Korea     Asian       +13553              128    100       HB    4       35         89    10   31    59    0.06      TaqMan
  Ding        2009   China     Asian       +13553              80     84        HB    0       35         45    0    30    54    0.046     sequencing
  Vural       2009   Turkey    European    -460                137    155       HB    18      64         55    29   74    52    0.76      F-LHPLC
  Guruvaiah   2014   India     Asian       -460                126    130       HB    27      59         40    25   72    33    0.2       sequencing
  Vural       2009   Turkey    European    +405                137    155       HB    3       44         90    4    39    112   0.78      F-LHPLC
  Guruvaiah   2014   India     Asian       +405                126    130       HB    10      46         70    19   59    52    0.73      sequencing
  Salem       2016   Tunisia   African     rs699947(-2578)     118    150       HB    20      63         35    29   76    45    0.76      TaqMan
  Almawi      2016   Bahrain   Asian       rs699947(-2578)     382    393       PB    64      183        135   50   178   165   0.85      TaqMan
  Gomes       2019   Brazil    Mixed       rs699947(-2578)     87     84        HB    27      38         22    18   41    25    \<0.001   PCR-RFLP
  Vural       2009   Turkey    European    rs699947 (-2578)    137    155       HB    22      63         52    25   78    52    \<0.001   F-LHPLC
  Salem       2016   Tunisia   African     rs833061            118    150       HB    30      55         33    32   76    42    0.82      TaqMan
  Almawi      2016   Bahrain   Asian       rs833061            382    393       PB    78      174        130   71   190   132   0.85      TaqMan
  Huang       2018   China     Asian       rs833061            118    130       HB    10      45         63    8    42    80    0.44      PCR-LDR
  Salem       2016   Tunisia   African     rs1570360 (-1154)   118    150       HB    19      42         57    18   57    75    0.17      TaqMan
  Almawi      2016   Bahrain   Asian       rs1570360 (-1154)   382    393       PB    45      140        197   44   131   218   \<0.001   TaqMan
  Li          2014   China     Asian       rs1570360 (-1154)   110    110       HB    3       29         78    5    30    65    0.53      PCR-RFLP
  Gomes       2019   Brazil    Mixed       rs1570360 (-1154)   87     84        HB    7       24         56    1    31    52    \<0.001   TaqMan
  Salem       2016   Tunisia   African     rs833068            118    150       HB    13      63         42    23   63    64    0.26      TaqMan
  Almawi      2016   Bahrain   Asian       rs833068            382    390       PB    51      175        156   34   200   156   0.006     TaqMan
  Salem       2016   Tunisia   African     rs3025020 (-583)    118    150       HB    10      40         68    8    52    90    0.89      TaqMan
  Almawi      2016   Bahrain   Asian       rs3025020 (-583)    382    393       PB    54      149        179   35   155   203   0.49      TaqMan
  Salem       2016   Tunisia   African     rs3025039 (+936)    118    150       HB    3       27         88    4    19    127   0.005     TaqMan
  Almawi      2016   Bahrain   Asian       rs3025039 (+936)    382    393       PB    5       81         296   7    68    318   0.141     TaqMan
  Gomes       2019   Brazil    Mixed       rs3025039 (+936)    86     85        HB    70      16               25   60                    PCR-RFLP

HWE: Hardy--Weinberg equilibrium; HB: hospital-based; SOC: source of control; SNPs: single-nucleotide polymorphism; PCR-RFLP: polymerase chain reaction and restrictive fragment length polymorphism; PCR-LDR: polymerase chain reaction-ligase detection reaction; F-LHPLC: fluorescence-labeled hybridization probes in a Light-Cycler; **\*** 1/1: mutant genotype, 1/2: heterozygous, 2/2: wide type.

Quantitative synthesis {#sec3-2}
----------------------

Significantly increased association were detected between five *VEGF* gene SNPs and PCOS susceptibility: rs699947 (Recessive model: OR = 1.74, 95% CI = 1.33--2.27, *P* = 0.346 for heterogeneity, *P* \< 0.001, [Figure 2](#F2){ref-type="fig"}, [Table 2](#T2){ref-type="table"}); rs833061 (Recessive model: OR = 1.71, 95% CI = 1.28--2.21, *P* = 0.794 for heterogeneity, *P* \< 0.001, [Figure 2](#F2){ref-type="fig"}, [Table 2](#T2){ref-type="table"}); rs1570360 (Recessive model: OR = 1.92, 95% CI = 1.36--2.72, *P* = 0.231 for heterogeneity, *P* \< 0.001, [Figure 2](#F2){ref-type="fig"}, [Table 2](#T2){ref-type="table"}); rs3025020 (Homo*z*ygote comparison: OR = 1.73, 95% CI = 1.13--2.65, *P* = 0.920 for heterogeneity, *P* = 0.011, [Figure 3](#F3){ref-type="fig"}, [Table 2](#T2){ref-type="table"}); rs3025039 (Dominant model: OR = 1.37, 95% CI = 1.01--1.85, *P* = 0.235 for heterogeneity, *P* = 0.042, [Figure 4](#F4){ref-type="fig"}, [Table 2](#T2){ref-type="table"}).

![Forest plot of PCOS risk associated with *VEGF* gene polymorphisms (rs699947, rs833061, rs1570360) (Recessive model) in the whole\
The squares and horizontal lines correspond to the study-specific OR and 95% CI. The area of the squares reflects the weight (inverse of the variance). The diamond represents the summary OR and 95% CI.](bsr-40-bsr20191691-g2){#F2}

![Forest plot of PCOS risk associated with *VEGF* gene polymorphisms (rs3025020 and +9812) (Homozygote comparison) in the whole\
The squares and horizontal lines correspond to the study-specific OR and 95% CI. The area of the squares reflects the weight (inverse of the variance). The diamond represents the summary OR and 95% CI.](bsr-40-bsr20191691-g3){#F3}

![Forest plot of PCOS risk associated with *VEGF* gene polymorphism (rs3025039) (Dominant model) in the whole. The squares and horizontal lines correspond to the study-specific OR and 95% CI\
The area of the squares reflects the weight (inverse of the variance). The diamond represents the summary OR and 95% CI.](bsr-40-bsr20191691-g4){#F4}

###### Total and stratified subgroup analysis for *VEGF gene* polymorphisms and PCOS susceptibility

  Variables           *N*   Case/     Allelic contrast       Homo*z*ygote comparison   Heterozygote comparison   Dominant model         Recessive model                                                                                                                                                
  ------------------- ----- --------- ---------------------- ------------------------- ------------------------- ---------------------- ----------------- ----------- ---------------------- ----------- ----------- ---------------------- ----------- ----------- ---------------------- ----------- -----------
  rs2010963 (-634)    3     632/622   0.89(0.75--1.05)       0.242                     0.152                     0.98(0.69--1.38)       0.233             0.899       **0.68(0.53--0.86)**   **0.339**   **0.002**   **0.74(0.59--0.93)**   **0.307**   **0.009**   **1.68(1.22--2.30)**   **0.197**   **0.001**
  +9812               2     212/183   **0.60(0.43--0.83)**   **0.892**                 **0.002**                 **0.33(0.16--0.68)**   **0.974**         **0.003**   0.83(0.53--1.31)       0.838       0.425       0.66(0.44--0.99)       1.000       0.047       0.57(0.28--1.16)       0.985       0.119
  +13553              2     208/184   0.86(0.40--1.85)       0.031                     0.697                                                              --          1.00(0.65--1.51)       0.153       0.991       0.93(0.42--2.02)       0.061       0.846                                          --
  -460                2     263/285   0.84(0.66--1.07)       0.487                     0.158                     0.72(0.44--1.18)       0.413             0.194       0.75(0.51--1.10)       0.626       0.142       0.74(0.52--1.06)       0.938       0.105       1.19(0.77--1.84)       0.278       0.422
  +405                2     263/285   0.86(0.41--1.77)       0.012                     0.673                     **0.48(0.23--1.00)**   **0.327**         **0.050**   0.90(0.38--2.15)       0.018       0.819       0.86(0.34--2.13)       0.009       0.731       0.85(0.42--1.73)       0.430       0.661
  rs699947 (-2578)    4     724/782   1.13(0.98--1.31)       0.258                     0.100                     1.28(0.94--1.73)       0.333             0.112       1.17(0.88--1.56)       0.596       0.288       1.15(0.93--1.42)       0.389       0.201       **1.74(1.33--2.27)**   **0.346**   **0.000**
  rs833061            3     618/673   1.09(0.93--1.28)       0.582                     0.294                     1.18(0.85--1.63)       0.809             0.325       1.01(0.79--1.29)       0.460       0.958       1.06(0.84--1.34)       0.484       0.620       **1.71(1.28--2.21)**   **0.794**   **0.000**
  rs1570360 (-1154)   4     697/737   1.08(0.91--1.27)       0.541                     0.390                     1.23(0.85--1.76)       0.259             0.268       1.15(0.79--1.68)       0.170       0.453       1.05(0.85--1.30)       0.578       0.626       **1.92(1.36--2.72)**   **0.231**   **0.000**
  rs833068            2     500/540   1.08(0.90--1.28)       0.909                     0.402                     1.28(0.85--1.94)       0.239             0.232       1.11(0.65--1.89)       0.071       0.713       1.05(0.82--1.35)       0.256       0.699       1.62(0.74--3.58)       0.061       0.230
  rs3025020 (-583)    2     500/540   **1.24(1.03--1.50)**   **0.719**                 **0.026**                 **1.73(1.13--2.65)**   **0.920**         **0.011**   1.07(0.83--1.39)       0.823       0.604       1.18(0.93--1.51)       0.744       0.176       **2.65(1.77--3.97)**   **0.974**   **0.000**
  rs3025039 (+936)    3     586/628   1.27(0.97--1.27)       0.276                     0.087                     0.87(0.35--2.18)       0.724             0.766       **1.43(1.05--1.96)**   **0.212**   **0.025**   **1.37(1.01--1.85)**   **0.235**   **0.042**   3.17(0.72--13.97)      0.004       0.128

*P*~h~: value of *Q*-test for heterogeneity test; *P*: *Z*-test for the statistical significance of the OR.

In opposite, several *VEGF* gene SNPs acts as a decreased association or protective effect for PCOS risk: rs2010963 (Heterozygote comparison: OR = 0.68, 95% CI = 0.53--0.86, *P* = 0.339 for heterogeneity, *P* = 0.002, [Figure 5](#F5){ref-type="fig"}, [Table 2](#T2){ref-type="table"}); +9812 (Allelic contrast: OR = 0.60, 95% CI = 0.43--0.83, *P* = 0.892 for heterogeneity, *P* = 0.002, [Figure 3](#F3){ref-type="fig"}, [Table 2](#T2){ref-type="table"}); +405 (Homo*z*ygote comparison: OR = 0.48, 95% CI = 0.23--1.00, *P* = 0.327 for heterogeneity, *P* = 0.050, [Figure 6](#F6){ref-type="fig"}, [Table 2](#T2){ref-type="table"}).

![Forest plot of PCOS risk associated with *VEGF* gene polymorphism (rs2010963) (Heterozygote comparison) in the whole\
The squares and horizontal lines correspond to the study-specific OR and 95% CI. The area of the squares reflects the weight (inverse of the variance). The diamond represents the summary OR and 95% CI.](bsr-40-bsr20191691-g5){#F5}

![Forest plot of PCOS risk associated with *VEGF* gene polymorphism (+405) (Allelic contrast) in the whole\
The squares and horizontal lines correspond to the study-specific OR and 95% CI. The area of the squares reflects the weight (inverse of the variance). The diamond represents the summary OR and 95% CI.](bsr-40-bsr20191691-g6){#F6}

Sensitivity analysis and bias diagnosis {#sec3-3}
---------------------------------------

We used a sensitivity analysis to determine whether modifying the meta-analysis inclusion criteria affected the results. No other single study influenced the summary OR qualitatively (data not shown). Egger and Begg's tests were performed to assess publication bias and the funnel plot symmetry was examined. Finally, no publication bias was observed (data not shown).

Gene--gene network diagram and interaction of online website {#sec3-4}
------------------------------------------------------------

String online server indicated that VEGF gene interacts with numerous genes. The network of gene--gene interaction has been illustrated in [Figure 7](#F7){ref-type="fig"}.

![Human VEGF interactions network with other genes obtained from String server\
At least 10 genes have been indicated to correlate with VEGF gene. KDR: vascular endothelial growth factor receptor 2; FLT1: vascular endothelial growth factor receptor 1; NRP2: neuropilin-2; HIF1A: hypoxia-inducible factor 1-α; NRP1: neuropilin-1; STAT3: signal transducer and activator of transcription 3; TGFB1: transforming growth factor β-1; EGF: pro-epidermal growth factor; IGF1: insulin-like growth factor 1; NOS3: nitric oxide synthase, endothelial.](bsr-40-bsr20191691-g7){#F7}

Discussion {#sec4}
==========

A strong association between increased serum VEGF levels and PCOS was previously reported, and a correlation between serum VEGF levels and increased ovarian stromal blood flow in women with polycystic ovaries was suggested \[[@B15],[@B16],[@B34],[@B35]\]. On the other hand, polymorphisms in the VEGF gene may lead to alterations in the production of this protein and may play an important role in the pathophysiology of PCOS, contributing to ovulatory dysfunction, infertility, and ovarian hyperstimulation syndrome, which are commonly observed in women with PCOS \[[@B36]\].

To combine the important of genetic etiology of PCOS, it makes sense to deep study the *VEGF* gene polymorphisms. There are at least 80 SNPs places in this gene (NCBI Gene association no: NT 007592). Among them, we searched several popular databases to select more comprehensive case--control studies about SNPs in *VEGF* gene, which have been reported more than once about PCOS disease. Finally, 11 SNPs \[rs2010963 (-634), +9812, +13553, -460, +405, rs699947 (-2578), rs833061, rs1570360 (-1154), rs833068, rs3025020 (-583), rs3025039 (+936)\] were identified.

Polymorphisms in the promoter region (loci: -2578, -1154 and -460) or intron 6 (loci: -583) or 5′-untranslated region (loci: +405, +963 and -634) or +534 have been associated with different levels of VEGF expression. It was reported that -2578 C, -460 T and +405 G alleles appear to correlate with altered VEGF expression levels \[[@B18],[@B20],[@B37]\]. In addition, a strong association between increased serum VEGF levels and PCOS was previously reported, and a correlation between serum VEGF levels and increased ovarian stromal blood flow in women with polycystic ovaries was suggested \[[@B15],[@B16],[@B34],[@B35]\]. Due to above items, these four SNPs have been widely reported in PCOS.

It is the first time to collect such more SNPs at one time, 11 SNPs containing 5203 cases and 5462 controls. The meaningful of our current analysis was that we found five SNPs (rs699947, rs833061, rs1570360, rs3025020, rs3025039) may act as a risk effect for the development of PCOS; moreover, three SNPs (rs2010963, +9812, +405) may have a protective influence for PCOS. Among above results, rs699947, rs3025020 and +405 polymorphisms were consistent with abnormal expression of VEGF gene in serum, and may be associated with PCOS risk through the serum *VEGF* levels. Some factors may be explained: First, different polymorphisms in the same gene may exert different effects on gene expression and function, leading to vary PCOS risks. Second, single genes or single environmental factors may not be likely to have direct effects on PCOS susceptibility, but complex interactions between genetic and environmental factors may be involved in the disease development. The last but not the least, if numbers of included studies were small, false-negative results may be detected for each polymorphism \[[@B41]\].

If one woman exists one or more significant following five SNPs (rs699947, rs833061, rs1570360, rs3025020, rs3025039) for VEGF from peripheral blood test, which may indicate that it is possible to increase the occurrence of PCOS for her in present time or at some point in the future. Therefore, it can be offer us some targets to intervene, such as lifestyle modification (reducing the BMI, obesity, high blood pressure, high blood fat and cardiovascular disease) for prevention status, regular gynecological examination (vaginal ultrasound or CT scans or endocrinology) to identify or rule out this disease and carry out treatments as soon as possible (oral contraceptive therapy, ovulation induction, high testosterone therapy, insulin sensitizer, GLP-I receptor agonist therapy, surgical treatment) \[[@B42]\]. To sum up, we wish to use this method to reduce the incidence of PCOS and improve the cure rate of early treatment. In addition, for another three decreased association SNPs (rs2010963, +9812, +405) and these no associated SNPs, it is not necessary to take corresponding monitoring measures at current moment.

In addition, we used the online analysis system-String to predict potential and functional partners ([Figure 7](#F7){ref-type="fig"}). Finally, ten genes were predicted. The average score was very high. Among them, the highest score of association was KDR and FLT1 (score = 0.999); however, TGFB1, EGF, IGF1 and NOS3 had the lowest scores (0.993). The action of VEGF is mediated by binding to tyrosine kinase receptors, VEGFR-1 (Fms-like tyrosine kinase: FLT1) and VEGFR-2 (kinase domain-containing receptor: KDR) \[[@B43]\]. Pan et al. demonstrated that HIF1A-mediated VEGF expression might be an important mechanism regulating ovarian luteal development in mammals *in vivo*, which may provide new strategies for fertility control and for treating PCOS \[[@B44]\]. Additional, IGF-1, TGFB1, STAT3 and NOS3 were just suggested to participate in the development of PCOS \[[@B45]\], rather than combined with VEGF. Above information predicted FLT1, KDR, and HIF1A may influence VEGF and regulate the PCOS development, which maybe become intervention and treatment target genes in the future.

Several limitations in our current analysis should be considered. First, unadjusted OR was used. Second, control sources were not all health women. Third, only four databases were searched for study retrieval, few relevant studies may be omitted. Fourthly, gene--gene interaction was missing. Fifth, other confounding factors such as age, BMI, lifestyle, total cholesterol, free androgen index, triglycerides and environment were not included and analyzed.

In summary, in the present meta-analysis, *VEGF* gene polymorphisms may be associated with PCOS susceptibility.
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